Rodriguez-Cerdeira et al J Clin Med Res • page no. to be assigned Table 1. Patient’s Characteristics Gender (female) Age Age at onset Illness duration at our first time (months) Previous treatments Fluoxetine Paroxetine Fluoxetine, Paroxetine Paroxetine Paroxetine Paroxetine Sertraline Sertraline Paroxetine Sertraline Fluoxetine Fluoxetine Paroxetine Paroxetine Paroxetine Paroxetine Fluoxetine Fluoxetine Fluoxetine Fluoxetine Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female Female 56 67 65 73 49 67 58 54 68 60 71 58 64 71 61 45 54 56 65 57 54 65 65 72 48 66 57 53 66 59 70 56 63 69 61 43 53 53 64 56 36 34 37 24 34 18 24 27 33 18 25 34 12 8 12 14 12 16 33 24 Mean ± SD 60.95 ± 7.57 59.65 ± 7.70 2.75 ± 9.48 mission, which is hypothesized to cause a reduction in both depressive and negative symptoms. Higher doses of the drug block the postsynaptic dopamine receptors, resulting in an improvement in symptoms of psychosis. It is an atypical an- tipsychotic drug and has a low incidence of extrapyramidal side effects [5]. Although substantial evidence indicates the efficacy of some antidepressants in treating psychogenic pain and so- matoform disorders, very few studies have investigated their possible therapeutic action in cases of BMS. The aim of this study was to demonstrate the efficacy and tolerability of ami- sulpride in a group of patients with BMS. Materials and Methods Patients for this study were recruited at the net of the hos- pitals of the National Galician Health Service in the North- western of Spain. Twenty-four subjects with BMS were screened consecutively for inclusion in this study, but only 22 patients, all female, gave their written consent and par- ticipated. All patients met the DSM-IV (Diagnostic and Sta- Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press™ | www.jocmr.org